Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study
Last Updated: Thursday, January 18, 2024
This clinical trial update presents the final prespecified overall survival analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). It was found that lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in these patients.
Advertisement
News & Literature Highlights